Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Tables)

Organization and Nature of Operations (Tables)
9 Months Ended
Sep. 30, 2022
Basis of Presentation and Going Concern Condition [Abstract]  
Schedule of company's subsidiaries consolidated financial statements
Name of Subsidiary   Place and date of Incorporation   Percentage of Ownership   Principal Activities

Avalon Healthcare System, Inc.



May 18, 2015

  100% held by ALBT   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)

Avalon (BVI) Ltd.

(“Avalon BVI”)


British Virgin Island

January 23, 2017

  100% held by ALBT  


is in process of being dissolved


Avalon RT 9 Properties LLC

(“Avalon RT 9”)


New Jersey

February 7, 2017

  100% held by ALBT   Owns and operates an income-producing real property and holds and manages the corporate headquarters

Avalon (Shanghai) Healthcare Technology Co., Ltd.
(“Avalon Shanghai”)



April 29, 2016

  100% held by AHS   Ceased operations

Genexosome Technologies Inc.




July 31, 2017

  60% held by ALBT   Dormant

Avactis Biosciences Inc.




July 18, 2018

  60% held by ALBT   Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers

Avactis Nanjing Biosciences Ltd.

(“Avactis Nanjing”)



May 8, 2020


100% held by


  Owns a patent

International Exosome Association LLC




June 13, 2019

  100% held by ALBT   Promotes standardization related to exosome industry